XK469

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About XK469

What it is

XK469 is an experimental anticancer compound, a quinoxaline that selectively inhibits topoisomerase II beta. It was tested in early clinical trials in people with advanced solid tumours and was not approved for use.

How genes come into it

XK469 is broken down mainly by aldehyde oxidase (AOX1). The gene studies listed, from its early trials, looked at AOX1 variants for its clearance, which varied widely between patients. The findings come from a few studies, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and XK469. Upload your DNA file to see which of these rows apply to you.

Rated evidence (1 rated variant)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

AOX1 rs10931910: Level 3. Metabolism/PK. 1.

Metabolism (2 findings)

Studies of how quickly the body processes this medication.

AOX1 rs10931910: Allele G is associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.

AOX1 rs10931910: Allele G is not associated with decreased clearance of XK469 in people with Neoplasms as compared to allele A.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Camptosar (Topoisomerase Inhibitors)

Hycamtin (Topoisomerase Inhibitors)

VePesid (Topoisomerase Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com